Lack of association of angiotensin II type 1 receptor A1166C gene polymorphism with the risk of end-stage renal disease

Figures & data

Figure 1. Flow chart of study selection.

Table 1. Characteristics of studies evaluating the effects of AT1R A1166C gene polymorphism on ESRD risk.

		ESRD				Controls				A allele (%)		HWE
Author	Ethnicity	AA	AC	CC	Total	AA	AC	CC	Total	Case	Control	p Value
Coll et al.11	Caucasian	55	44	5	104	54	66	11	131	74	66.4	0.33
Lee et al.16	Asian	20	4 (AC + CC)		24	94	11	0	105	–	–	0.852
Chang et al.12	Asian	106	10 (AC + CC)		116	122	7 (AC + CC)		129	–	–	–
Lau et al.14	Asian	30	2	0	32	84	10	0	94	97	95	0.862
Buraczynska et al.8	Caucasian	346	322	77	745	322	182	16	520	68	80	0.319
Papp et al.13	Caucasian	37	29	4	70	78	67	5	150	73.7	75	0.113
Huang et al.15	Asian	42	5	0	47	100	20	0	120	94.7	91.7	0.609
Zsom et al.10	Caucasian	118	92	12	222	100	88	12	200	73.9	72	0.435

Notes: HWE, Hardy–Weinberg equilibrium; ESRD, end-stage renal disease.

Figure 2. Association between A allele and ESRD risk for overall populations.

Figure 3. Association between AA genotype and ESRD risk for overall populations.

Figure 4. Association between CC genotype and ESRD risk for overall populations.

Figure 5. Association between AC genotype and ESRD risk for overall populations.

Table 2. Meta-analysis of the association of AT1R A1166C gene polymorphism with ESRD risk.

Study	Ethnicity	Studies	Q test (p value)	Model selected	OR (95% CI)	p Value
Log-additive model	Caucasian	4	0.001	Random	0.935(0.520–1.351)	–
A versus C	Overall	6	<10^−4	Random	1.049(0.671–1.640)	0.834
	Caucasian	4	<10^−4	Random	0.954(0.576–1.578)	0.853
	Asian	2	0.938	Fixed	1.655(0.711–3.855)	0.243
AA versus (AC + CC)	Overall	8	0.001	Random	0.957(0.637–1.438)	0.832
	Caucasian	4	<10^−4	Random	0.957(0.529–1.731)	0.884
	Asian	4	0.372	Fixed	0.994(0.567–1.742)	0.982
CC versus (AC + AA)	Overall	6	0.016	Random	1.527(0.681–3.424)	0.304
	Caucasian	4	0.003	Random	1.381(0.529–3.605)	0.510
	Asian	2	0.945	Fixed	2.735(0.379–19.762	0.319
AC versus (AA + CC)	Overall	6	0.057	Random	0.942(0.687–1.292)	0.712
	Caucasian	4	0.036	Random	0.997(0.709–1.402)	0.987
	Asian	2	0.950	Fixed	0.584(0.245–1.394)	0.225
Sensitivity analysis
A versus C	Overall	6	<10^−4	Random	1.049(0.671–1.640)	0.834
	Caucasian	4	<10^−4	Random	0.954(0.576–1.578)	0.853
	Asian	2	0.938	Fixed	1.655(0.711–3.855)	0.243
AA versus (AC + CC)	Overall	7	<10^−4	Random	1.007(0.646–1.569)	0.976
	Caucasian	4	<10^−4	Random	0.957(0.529–1.731)	0.884
	Asian	3	0.378	Fixed	1.259(0.623–2.545)	0.522
CC versus (AC + AA)	Overall	6	0.016	Random	1.527(0.681–3.424)	0.304
	Caucasian	4	0.003	Random	1.381(0.529–3.605)	0.510
	Asian	2	0.945	Fixed	2.735(0.379–19.762)	0.319
AC versus (AA + CC)	Overall	6	0.057	Random	0.942(0.687–1.292)	0.712
	Caucasian	4	0.036	Random	0.997(0.709–1.402)	0.987
	Asian	2	0.950	Fixed	0.584(0.245–1.394)	0.225

Notes: OR, odds ratio; CI, confidence interval.

Table 3. Characteristics of univariate meta-regression analysis.

Covariate	Coefficient	95% CI	p Value
Age	0.0016	−1.635 to 1.638	0.998
Male/female ratio	0.317	−2.338 to 2.973	0.78
Ethnicity	0.1059	−2.629 to 2.842	0.928

Figure 6. Publication bias for the analysis of association of AT1R A1166C gene polymorphism with ESRD risk for overall populations.

Coll E, Campos B, Nunez DG, et al. Association between the A1166C polymorphism of the angiotensin II receptor type 1 and progression of chronic renal insufficiency. J Nephrol. 2003;16:357–364

 PubMed Web of Science ®Google Scholar

Lee KB, Kim UK. Angiotensinogen and angiotensin II type 1 receptor gene polymorphism in patients with autosomal dominant polycystic kidney disease: effect on hypertension and ESRD. Yonsei Med J. 2003;44:641–647

 PubMedGoogle Scholar

Chang HR, Cheng CH, Shu KH, et al. Study of the polymorphism of angiotensinogen, anigiotensin-converting enzyme and angiotensin receptor in type II diabetes with end-stage renal disease in Taiwan. J Chin Med Assoc. 2003;66:51–56

 PubMedGoogle Scholar

Lau YK, Woo KT, Choong HL, et al. Renin-angiotensin system gene polymorphisms: its impact on IgAN and its progression to end-stage renal failure among Chinese in Singapore. Nephrol Physiol. 2004;97:1–8

 Google Scholar

Buraczynska M, Ksiazek P, Drop A, et al. Genetic polymorphisms of the renin-angiotensin system in end-stage renal disease. Nephrol Dial Transplant. 2006;21:979–983

 PubMed Web of Science ®Google Scholar

Papp F, Friedman AL, Bereczki C, et al. Renin-angiotensin gene polymorphism in children with uremia and essential hypertension. Pediatr Nephrol. 2003;18:150–154

 PubMedGoogle Scholar

Huang HD, Lin FJ, Li XJ, et al. Genetic polymorphisms of the renin–angiotensin–aldosterone system in Chinese patients with end-stage renal disease secondary to IgA nephropathy. Chin Med J. 2010;123:3238–3242

 PubMed Web of Science ®Google Scholar

Zsom M, Fulop T, Zsom L, et al. Genetic polymorphisms and the risk of progressive renal failure in elderly Hungarian patients. Hemodial Int. 2011;15:501–508

 PubMed Web of Science ®Google Scholar